Biochemical and structural characterization of Cryptosporidium parvum Lactate dehydrogenase by Cook, W.J. et al.
Biochemical and Structural Characterization of 
Cryptosporidium parvum Lactate Dehydrogenase 
 
 
William J. Cook
a*
, Olga Senkovich
b*
, Agustin Hernandez
c
, Haley Speed
b
, Debasish 
Chattopadhyay
b,d †
 
a
Department of Pathology, 
b
Center for Biophysical Sciences and Engineering, University of 
Alabama at Birmingham, Birmingham, AL  35294 
c
Instituto de Bioquímica Vegetal y Fotosintesis (CSIC/U. Sevilla), Avda. Americo Vespucio 
49, Seville 41092, Spain 
Department of Medicine, University of Alabama at Birmingham, Birmingham, AL  35294 
 
†
 Corresponding author: debasish@ uab.edu 
      Phone: (205) 934-0124 
      Fax:    (205) 934-0480 
*These authors contributed equally 
 
 
Keywords: Crystal structure, lactate dehydrogenase, Cryptosporidium parvum 
*Manuscript
Click here to view linked References
Abstract 
The protozoan parasite Cryptosporidium parvum causes waterborne diseases worldwide. 
There is no effective therapy for C. parvum infection.  The parasite depends mainly on 
glycolysis for energy production.  Lactate dehydrogenase is a major regulator of glycolysis.  
This paper describes the biochemical characterization of C. parvum lactate dehydrogenase 
and high resolution crystal structures of the apo-enzyme and four ternary complexes. The 
ternary complexes capture the enzyme bound to NAD/NADH or its 3-acetylpyridine analog 
in the cofactor binding pocket, while the substrate binding site is occupied by one of the 
following ligands: lactate, pyruvate or oxamate. The results reveal distinctive features of the 
parasitic enzyme.  For example, C. parvum lactate dehydrogenase prefers the acetylpyridine 
analog of NADH as a cofactor.  Moreover, it is slightly less sensitive to gossypol inhibition 
compared with mammalian lactate dehydrogenases and not inhibited by excess pyruvate.  
The active site loop and the antigenic loop in C. parvum lactate dehydrogenase are 
considerably different from those in the human counterpart.  Structural features and 
enzymatic properties of C. parvum lactate dehydrogenase are similar to enzymes from related 
parasites.  Structural comparison with malate dehydrogenase supports a common ancestry for 
the two genes.  
1. Introduction 
The apicomplexan parasite Cryptosporidium parvum causes waterborne diseases and 
poses a threat to water supplies worldwide (Leitch & He, 2012; Shirley et al., 2012).  The 
parasite infects a wide spectrum of hosts including humans and other mammals (Santin, 
2013).  In developing countries, Cryptosporidium is a significant cause of diarrhea, 
contributing to malnutrition in children.  Although infection causes self-limited diarrhea in 
healthy adults, symptoms can be serious, long lasting, and often lethal in 
immunocompromised individuals (Leitch & He, 2012; Shirley et al., 2012).  Currently, there 
is no satisfactory chemotherapy or vaccine against cryptosporidiosis.   
One of the major impediments to identifying therapeutic targets in Cryptosporidium is 
the lack of knowledge about its biochemical and metabolic pathways.  Genome sequencing 
indicates that C. parvum does not have a functional mitochondrion and lacks an active Krebs’ 
cycle (Abrahamsen et al., 2004) but encodes all glycolytic enzymes. Since the parasite 
appears to depend primarily on anaerobic oxidation of glucose for energy metabolism 
(Coombs, 1999, Denton et al., 1996), enzymes in the glycolytic pathway and those that play 
regulatory roles may offer potential targets for anti-cryptosporiodial drugs.  Studies with 
other apicomplexan parasites have shown that inhibition of glycolysis may be a useful 
strategy for antiparasitic therapy (Basco et al., 1995; Bressi et al., 2000; Dando et al., 2001; 
Deck et al., 1998; Wang, 1984).  To develop a detailed understanding of the key regulatory 
mechanisms that are characteristic of the parasite, we are studying a number of enzymes that 
control glycolysis in C. parvum (Senkovich et al, 2005; Cook et al., 2009; Cook et al., 2012).   
Lactate dehydrogenase (LDH) plays a central role in regulating glycolysis.  LDH is a key 
enzyme for the anaerobic respiration step in which pyruvate is reduced to lactate with the 
concomitant oxidation of NADH to NAD
+
 (Everse & Kaplan, 1973).  This reaction is crucial 
for progression of glycolysis.  Firstly, removal of pyruvate allows glycolysis to progress in 
the direction toward generating more ATP molecules.  Secondly, it regenerates NAD
+
, which 
is required for the oxidation of glyceraldehyde 3-phosphate in glycolysis, a step catalyzed by 
the glycolytic enzyme glyceraldehyde 3-phosphate dehydrogenase. 
 In humans there are two major forms of LDH.  The M-form is found predominantly in 
anaerobic tissues such as skeletal muscle, and the H-form is present mostly in aerobic tissues 
such as cardiac muscle.  The M-form and H-form enzymes are 78% identical in their primary 
sequences.  Although the primary sequence of LDH is highly conserved among various 
organisms, LDHs of a number of protozoan parasites including C. parvum (CpLDH) differ 
from human LDH in several key amino acid positions, and some possess a unique insertion in 
the active site loop (Fig. 1) (Deck et al., 1998; Gomez et al., 1997; Dunn et al., 1996; 
Sessions et al., 1997; Winter et al., 2003).  LDHs of certain protozoa also demonstrate 
distinctive structural and biochemical properties.  For example, the P. falciparum enzyme 
(PfLDH) exhibits 200-300 fold higher activity with the NADH analog 3-acetyl pyridine 
adenine dinucleotide (APADH) than the human M and H isozymes (Gomez et al., 1997).  
Biochemical differences between human LDH and PfLDH have been exploited for the 
development of a diagnostic tool for detection of malaria in the blood of infected individuals 
(Klenerman & Dickson, 1992; Makler & Hinrichs, 1993) and development of selective 
inhibitors of the parasitic enzyme (Gomez et al., 1997).  Differences in the cofactor binding 
sites of LDH from human and P. falciparum allow derivatives of the natural product gossypol 
to selectively inhibit parasitic LDHs (Dando et al., 2001; Deck et al., 1998; Royer et al., 
1998).  Structural analysis of LDH from two different species of plasmodium showed that 
these enzymes possessed distinctive features, which may be useful for development of 
species-specific inhibitors of the plasmodium enzymes (Dunn et al., 1996; Sessions et al., 
1997; Winter et al., 2003). 
Here we describe the results of enzymatic and structural analyses of CpLDH.  We 
discuss the crystal structures of the apo-enzyme and four ternary complexes with substrate, 
inhibitor (oxamate) or product bound at the active site.  To visualize the differences in the 
binding of NAD and APAD at the cofactor binding pocket, structures of pyruvate complexes 
were determined separately with each cofactor.  We also compare the properties of CpLDH 
with LDHs from human and apicomplexan parasites. Finally, we present a comparison of the 
structures of CpLDH and C. parvum malate dehydrogenase (CpMDH). 
2. Materials and Methods 
2.1. Preparation of enzyme 
Expression and purification of CpLDH have been described in detail (Senkovich et al., 
2005).  Briefly, the recombinant protein was expressed in E. coli strain Rosetta (DE3)pLysS. 
The bacterial cell pellet was lysed in buffer I (50 mM Tris-HCl, 1 mM benzamidine 
hydrochloride, 0.1 mM PMSF, 5 mM DTT and 1 mM EDTA, pH 7.4). The resulting 
suspension was subjected to centrifugation at 20,000 rpm for 30 min, and the supernatant was 
treated with 0.2% protamine sulfate for 20 min at 4C. CpLDH was precipitated from 
clarified cell-free extract by adding ammonium sulfate to 40% saturation. The resuspended 
pellet was dialyzed overnight in buffer I and applied to a Superdex 200 size exclusion column 
(Amersham Pharmacia). As reported previously, enzymatically active CpLDH eluted from 
the Superdex 200 column as a tetramer as calculated from the elution volume and = nearly 
homogeneous purified protein migrated as a major band of approximately 33 kDa on SDS-
PAGE (Senkovich et al., 2005).  Fractions containing enzymatically active CpLDH were 
pooled, dialyzed against buffer II (50 mM Tris-HCl, 1 mM EDTA and 5 mM DTT, pH 8.0) 
and applied to a Mono Q 10/10 column (Amersham Pharmacia). After washing the column 
with buffer II, the bound protein was eluted using a linear gradient of sodium chloride (0-0.3 
M) in 15 column volumes of buffer II. Purified protein was concentrated by ultrafiltration to a 
final concentration of 21 mg/ml. Sequencing of the recombinant plasmid revealed that the 
DNA encodes alanine at position 202, lysine at position 265 and glutamate at position 311 
(see Footnote for explanation of LDH numbering), while the database sequence for CpLDH 
(GenBank accession No. AF274310) has valine, arginine and lysine, respectively, at these 
positions (Fig. 1).  Similar results were obtained in multiple PCR experiments.  We do not 
know if the sequence differences are PCR errors, mutations corresponding to DNA 
polymorphism, or if there are errors in the GenBank database. 
2.2. Enzyme activity 
LDH enzyme assays were performed in a temperature-controlled UV-Visible 
spectrophotometer (DU740, Beckman Instruments) using standard methods (Dando et al., 
2001).  Reaction velocities were measured at 25

C for 1 min by following decrease or 
increase in absorbance at 340 nm due to oxidation of NADH or reduction of NAD
+
.  The 
CpLDH activity in the direction of reduction of pyruvate to lactate was measured in 50 mM 
sodium acetate buffer, pH 5.5, and activity in the direction of oxidation of lactate to pyruvate 
was measured in 50 mM Tris-HCl buffer, pH 9.1.  A typical reaction mixture contained 
substrate (10 M - 5 mM pyruvate or 50 μM - 20 mM lactate) and cofactor (3 - 150 μM 
NADH or 10 - 600 μM NAD+); enzyme reaction was initiated by adding 1 - 5 μg of purified 
CpLDH.  The pH dependence of the CpLDH activity was determined using three buffers with 
overlapping pHs: 50 mM sodium acetate, pH 3.6 - 6.0, 50 mM sodium phosphate, pH 5.6 - 
7.2 and 50 mM Tris-HCl, pH 6.6 - 9.5.  When APAD
+
/APADH was used as cofactor, 
reaction velocities were measured by following increase or decrease in absorbance at 363 nm 
due to reduction of APAD
+
 or oxidation of APADH.  The kinetic parameters (Michaelis 
constant Km, maximum velocity Vmax and turnover rate Kcat) for substrates and cofactors and 
the inhibitory constant Ki value for gossypol were determined by non-linear regression using 
ANEMONA Excel templates (Hernandez and Ruiz, 1998). 
2.3. Crystallization and data collection 
CpLDH was crystallized under several different conditions at 4C.  As reported 
previously crystals of the apo enzyme suitable for data collection were grown from 16.5% 
(v/v) PEG 2000, 0.1 M Tris-HCl (pH 7.0) and 0.08% n-octyl-β-D-glucopyranoside 
(Senkovich et al., 2005).  For crystallization of the ternary complexes, the concentrated 
protein was incubated with 1 mM substrate (pyruvate, lactate or oxamate) and 100 μM 
NADH, NAD
+
 or APAD
+
 for an hour on ice.  Crystals of the ternary complexes were 
obtained at 4C using 1.45-1.65 M ammonium sulfate in 0.1 M sodium cacodylate (pH 6.75 
to 7.25).  
X-ray diffraction data were collected under cryogenic conditions (-180C) using a 
cryopreservative solution containing 25% glycerol in the reservoir solution.  Intensity data 
were processed using Denzo and Scalepack (Otwinowski & Minor, 1997).  Crystals of apo 
CpLDH belong to space group P3212 and contain four monomers (two dimers) in the 
asymmetric unit.  Crystals of the ternary complexes belong to space group P3221 and contain 
two monomers (one dimer) in the asymmetric unit. 
2.4. Structure determination and refinement 
The crystal structure of the ternary complex of CpLDH with pyruvate and APAD
+
 was 
solved by molecular replacement using the CNS program package (Brünger et al., 1998) with 
data in the range 20 - 4.5 Å for the rotation and translation searches.  Calculation of a self-
rotation function revealed a strong peak at kappa = 180º, indicating the presence of a 
noncrystallographic two-fold axis.  Using a search model of CpLDH built from PfLDH 
(PDBID 1T2D), positions of the two monomers in the asymmetric unit were determined.  
The correct enantiomorphic space group (P3221) was determined from the values of 
correlation coefficient and R factor in the molecular replacement trials with the two 
enantiomorphic space groups.  Refinement of the structure was performed initially by 
simulated annealing using CNS with the stereochemical parameter files defined by Engh and 
Huber (1991).  No sigma cutoff was applied to the data.  Ten percent of the data was 
randomly selected and removed prior to refinement for analysis of the free R factor.  The two 
subunits in the asymmetric unit were restrained by the non-crystallographic symmetry 
throughout the simulated annealing refinement.  The molecular model was improved by 
cycles of manual fitting to 2Fo-Fc electron density maps using the program COOT (Emsley 
et al., 2010) alternating with refinement.   
An Fo-Fc electron density map allowed placement of APAD
+
 and pyruvate in each 
monomer.  As the refinement progressed, water molecules were added by using the water-
picking routines in CNS and COOT.  All water molecules were verified by inspection of the 
maps.  In the later stages of refinement, noncrystallographic symmetry restraints were 
removed, and the restrained refinement option in REFMAC5 (Murshudov et al., 2011) was 
used.   
The structures of the apo enzyme and the other three ternary complexes were solved by 
molecular replacement using the LDH dimer from the C. parvum LDH/APAD
+
/pyruvate 
structure as the search model. The refinement procedure was the same in each case as 
described above.  Atomic coordinates and structure factors have been deposited in the Protein 
Data Bank with PDBIDs 4ND1 (NAD
+
/oxamate complex), 4ND2 (APAD
+
/pyruvate 
complex), 4ND3 (NADH/lactate complex), 4ND4 (NAD
+
/pyruvate) and 4ND5 (apo 
enzyme)
†
. 
3. Results 
As reported previously purified recombinant CpLDH eluted as a tetramer as revealed by size 
exclusion chromatography (Senkovich et al., 2005). On SDS PAGE analysis the purified 
protein migrated as a single band of approximately 33 kDa.      
3.1. Enzyme activity 
Using buffer solutions of overlapping pH, we determined pH optima for LDH reactions 
in both directions.  The optimal pH for the reduction of pyruvate was 5.0 - 5.5, but the 
optimal pH for the oxidation of lactate was 9.0 - 9.5 (Fig. 2A and B).  In Table 1, kinetic 
parameters for CpLDH are compared with those of human isoforms, P. falciparum and T. 
gondii LDH.  Like PfLDH, CpLDH prefers APAD
+
 and APDH over NAD
+ 
and NADH, 
respectively, as a cofactor.  The kcat of CpLDH was two-fold greater for APADH than for 
NADH.  Similarly, the enzymatic activity of CpLDH was ~5 times higher with APAD
+
 than 
with NAD
+
 as a cofactor.  On the other hand, the human enzymes show ~17-20 fold higher 
activity with NAD
+
 as compared with APAD
+
.  Therefore, with APAD
+
 the activity of 
CpLDH is 100 fold higher than the human counterparts. In comparison PfLDH is 200 times 
more active with APAD
+
 than the human enzyme (Gomez et al., 1997).   In the case of 
CpLDH a small but significant negative cooperativity towards pyruvate was observed (Hill 
coefficient h= 0.69±0.00). However, in the case of NADH, the estimated cooperativity (Table 
1) was not significant since the sum of least-squares after fitting the data to a Hill model was 
nearly identical to that observed after a pure Michaelis-Menten fit (data not shown). On the 
other hand, a negative cooperativity was observed when APAD
+ 
was used as a cofactor. 
Gossypol and a number of its derivatives are known to inhibit LDH activity (Deck et al., 
1998; Conners et al., 2005).  As seen with other LDHs (Olgiati & Toscano, 1983), the 
                                                 
†
 PDBIDs are shown in italics throughout this manuscript 
mechanism of inhibition of CpLDH by gossypol is competitive with NADH (Fig. 2C).  The 
observed Ki value for gossypol (11.6 µM) for CpLDH is in the same range but slightly higher 
than for the human enzyme (1.9 and 1.4 µM for M and H-forms, respectively; Gomez et al., 
1997).   
In general, LDHs are inhibited by excess pyruvate, presumably due to the formation of 
an NAD
+
/pyruvate complex (Wang, 1977).  A distinctive biochemical feature of some 
protozoan LDHs is their insensitivity to high pyruvate concentration.  As shown in Fig. 2D, 
CpLDH does not display any measurable inhibition to pyruvate concentrations up to at least 
20 mM.   
3.2. General description and quality of the structures 
Crystal structures of CpLDH were determined in the apo form and as ternary complexes 
containing the following: pyruvate and NAD
+
, lactate and NADH, oxamate and NAD
+
, 
pyruvate and APAD
+
.  Statistics for data collection are shown in Table 2.  Refinement 
statistics and Molprobity analyses (Davis et al., 2007) are listed in Table 3. 
3.2.1. Apo CpLDH 
Apo CpLDH crystallizes in the space group P3212, and the crystal structure contains two 
dimers (two half tetramers) in the asymmetric unit.  The crystallographic symmetry pairs for 
each dimer form the functional tetramers.  The model includes residues 17-98 and 112-330 
for monomer A, 17-98 and 112-329 for monomer B, 18-98 and 112-329 for monomer C, and 
18-98 and 112-327 for monomer D.  The electron density for C-terminal residues and the 
active site loop (residues 99-111) was extremely weak, and those residues could not be 
modeled.  The four CpLDH monomers in the asymmetric unit are nearly superimposable.  
Compared to monomer A, the root mean square deviation for all Cα-atoms is 0.327 Å for B 
to A, 0.353 Å for C to A and 0.332 Å for D to A. 
3.2.2. Ternary complexes of CpLDH  
Crystals of the four ternary complexes belong to space group P3221.The asymmetric unit 
contains two monomers related by non-crystallographic 2-fold symmetry (Fig. 3A).  The 
complete tetramer is formed with their symmetry partners related by a crystallographic 2-fold 
axis.  In each complex the model includes residues 17-333 for each chain (see note at the end 
of the manuscript); only the last four C-terminal residues were not visible in the electron-
density maps.  The arrangement of the monomers in the tetramer is similar to that seen in 
other LDH structures.  The two monomers in the asymmetric unit form the major interface 
and bury approximately 7900 Å
2
 of surface area.  Superposition of all four complex 
structures, using monomer A of the CpLDH/NAD
+
/pyruvate structure as the reference, 
results in r.m.s.d. values of 0.113 Å for CpLDH/NADH/lactate, 0.176 Å for CpLDH/NAD
+
/ 
oxamate, and 0.107 Å for CpLDH/APAD
+
/pyruvate. 
As shown in Supplementary Fig. S1, in all four ternary complexes the NAD
+
/NADH site 
is fully occupied in both monomers in the asymmetric unit.  Electron density for substrate 
molecules was also excellent in each subunit of all complexes except in the NADH/lactate 
complex, in which the density for lactate was clear only in subunit A.  Average B-factors for 
the co-factor and substrate/analog molecules are comparable to those of the protein residues 
in each complex (Table 3).  In all cases the CpLDH monomers in the asymmetric unit and the 
bound cofactors are nearly superimposable.  The root mean square deviation between 
monomers A and B for all 317 Cα atoms is 0.278 Å for CpLDH/NAD+/pyruvate, 0.465 Å for 
CpLDH/NADH/lactate, 0.379 Å for CpLDH/NAD
+
/oxamate, and 0.347 Å for 
CpLDH/APAD
+
/pyruvate. 
The overall quality of the structures of CpLDH is excellent.   Only Ala164 and Gly283 in 
each monomer exhibit phi, psi angles in non-allowed regions of the Ramachandran plot.  The 
residue corresponding to Ala164 is glycine in human and plasmodium LDH. All of the 
structures contain several glycerol molecules associated with each chain. 
 
3.3. NADH/APADH and substrate binding sites 
In the following description monomer A from the ternary complex 
CpLDH/NAD
+
/pyruvate (4ND4) will be used as the template unless otherwise stated.  
CpLDH monomers are composed of two domains with the active site located at the interface 
of the two domains (Fig. 3A).  The NAD-binding domain (shown in light pink in Fig. 3A) is 
characterized by a typical Rossmann fold consisting of a six-stranded parallel β-sheet flanked 
by α-helices. As shown in Fig. 3B and C, the adenine ring of the cofactor lies in a 
hydrophobic pocket formed by Ile27, Phe52, Ile54, Tyr85, Ala98, Ile119 and Val123 and 
packs against the side chains of Ile54 and Ala98.  The hydroxyl oxygen atoms O2B and O3B 
of the adenosine ribose ring are hydrogen bonded to the side chain oxygen atoms of Asp53.  
The diphosphate oxygen atoms are hydrogen bonded to water molecules and main chain N 
atoms of Gln31 and Ile32.  The nicotinamide ring packs against the hydrophobic side chains 
of Ile32, Ile138 and Pro250 (Fig. 3B).  The hydroxyl oxygen atoms O2D and O3D of the 
nicotinamide-ribose are hydrogen bonded to the ND2 atom of Asn140 and the OG atom of 
Ser99, respectively (Fig. 3D).  
The conserved catalytic residues Arg171 and His195 (CpLDH numbering), which bind 
the substrate, are located in the catalytic domain (shown in magenta in Fig.3A).  The carboxyl 
oxygen atoms (O1 and O2) of pyruvate form hydrogen bonds with the side chain nitrogen 
atoms of Arg171, and O2 forms an additional contact with NH2 of Arg109.  Atom O3 of 
pyruvate forms hydrogen bonds with atom NE2 of His195 and atom NE of Arg109 (Fig. 3D). 
3.4. Changes to apo-LDH on binding of substrate and cofactor  
As expected, the overall structure of CpLDH is similar in the apo-form and various 
ternary complexes. Compared to monomer A in the CpLDH/NAD
+
/pyruvate structure, the 
r.m.s.d. deviation for all Cα-atoms is 0.883 Å. The major differences between the apo and 
complex structures are confined to five regions, and four of these regions are involved in 
binding the cofactor and the substrate. The most obvious difference is the absence of electron 
density for the active site loop (residues 99-111, Fig. 4A), indicating disorder in the apo 
structure.  The second region, residues 138-145, corresponds to the end of a short loop and 
the beginning of helix 4 (Fig. 4B).  This segment moves closer to the active site loop when 
the active site is occupied.  The third region, residues 194-198, includes the conserved 
catalytic residue His195.  The side chain of His195 assumes a different rotamer configuration 
in the apo structure (Fig. 4C). This is different from the plasmodium and toxoplasma apo 
LDH structures, in which the side chain of the catalytic histidine residue has the same 
rotamer conformation as in substrate-bound LDH.  The fourth region (residues 234-245) is at 
the end of a long helix (Fig. 4D). This helix moves closer to the substrate in the 
CpLDH/NAD
+
/pyruvate structure.  Finally, the long C-terminal helix moves closer to the 
adjacent beta sheet to form a slightly more compact structure overall (Fig. 4A), but it does not 
seem to have any effect on the binding site. 
4. Discussion 
4.1. Comparison to human LDH 
The crystal structures of human LDH have been determined in the apo form, as a binary 
complex with NADH (Dempster et al., 2014) and as ternary complexes (Read et al., 2001).  
The sequence identity between CpLDH and human LDH is 25%, and the r.m.s.d. value for 
the superposition of CpLDH (NAD
+
/oxamate complex) with the H form of human LDH 
bound to NADH and oxamate (PDBID: 1I0Z) is 1.050 Å. The overall architecture of CpLDH 
is similar to the structure of human LDH, and most of the structural differences are small and 
involve peripheral loops and the C-terminus (Fig. 5A).  However, there are two major 
differences. Conformation of the active site loop in CpLDH (residues 99-111) is considerably 
different from human LDH, even though it contains the same number of residues in both 
enzymes.  Moreover, the helix-loop segment (residues 243-245) in the CpLDH structure also 
moves closer to the active site loop.  A close-up view of the two above mentioned loops in 
the two structures is displayed in Fig. 5B.  Electron density for the CpLDH residues in both 
loops was well defined (see Supplementary Fig. S2).  The other major conformational 
difference between these structures is in the antigenic loop (CpLDH residues 210-225, Fig. 
5C, also Supplementary Figure S3).  This loop has a similar conformation in the 
cryptosporidium, plasmodium and toxoplasma LDH structures, but in the human LDH 
structure the loop pivots on residues Leu211 and Trp227 (corresponding to Leu212 and 
Ile225 in CpLDH) away from the N-terminus of the adjacent monomer in the tetramer.  The 
N-terminal extension in human LDH structures is not present in cryptosporidium, 
plasmodium or toxoplasma LDH and probably explains the large conformational change of 
the antigenic loop with respect to parasitic LDH. The four critical residues involved in 
binding the substrate (Arg109, Asn140, Arg171 and His195) are conserved in human and 
CpLDH.  However, there are significant differences in the cofactor binding site that explain 
the lower affinity for NAD
+
/NADH in the parasitic enzyme (discussed in section 4.4). 
4.2. Comparison to Plasmodium and Toxoplasma LDH 
The crystal structures of LDH from T. gondii (TgLDH; Kavanagh et al., 2004) and three 
species of the malaria parasite have been determined: P. falciparum ((Dunn et al., 1996), P. 
vivax (Chaikuad et al., 2005) and P. berghei (Winter et al., 2003).  LDH structures from the 
three plasmodium species are almost identical, so only the P. falciparum LDH structure 
(PfLDH) will be used for comparison.   
Results of primary sequence alignment using the CLUSTAL Omega server 
(http://www.ebi.ac.uk) (Goujon et al., 2010; Sievers et al., 2011) show that identity between 
LDHs from various species varies roughly in the range 41-49% based on the evolutionary 
relationship between the organisms.  Thus, pair-wise sequence identities between CpLDH 
and LDH from P. falciparum and T. gondii are 41% and 41%, respectively, while the P. 
falciparum and T. gondii sequences are 49% identical.  The r.m.s.d. values for the 
superposition of CpLDH (NAD
+
/oxamate complex) with TgLDH (PDBID: 1PZF) and 
PfLDH (PDBID: 1T2D) are 0.956 Å and 1.066 Å, respectively.  Although the overall 
architecture of CpLDH is similar to the other two parasitic LDH structures, the orientation of 
the active site loop in CpLDH is quite different, primarily because this loop contains five 
fewer residues in CpLDH (Figs. 1 and 6A,B).  The extra residues in the plasmodium and 
toxoplasma LDH structures cause the loop to protrude from the active site, while the absence 
of these extra residues in CpLDH results in a loop in which three residues (Ile100, Pro101 
and Gly102) bulge out to form the surface of the binding site cavity (Fig. 6B).  The 
conformation of the other loop that covers the active site cleft (residues 243-246; Fig. 6B) is 
somewhat different than in plasmodium LDH.  This loop is closer to the helix (residues 222-
243) o the other side of the binding cleft compared to the PfLDH structure, which has a two 
residue deletion in the helix.  The remaining structural differences are small and involve 
peripheral loops and the C-terminus.  The antigenic loop of CpLDH (residues 210-225) is 
similar to that in the PfLDH and TgLDH structures.   
The four residues involved in binding the substrate and co-factor are conserved in all 
three parasitic enzymes.  In PfLDH a leucine residue is present in the position equivalent to 
Met163 in CpLDH, while in TgLDH the equivalent residue is also methionine. Both PfLDH 
and TgLDH contain a proline residue in the position equivalent to Pro250 in CpLDH. 
Gossypol and a number of its derivatives have been reported to inhibit PfLDH at low 
micromolar or nanomolar concentration ranges.  So far structure any LDH- gossypol complex 
has not been determined.  Crystal structures of PfLDH with small gossypol-like compounds 
have been reported (1U4O, 1U4S, 1U5C, 1U5A).  These naphthalene derivatives are much 
weaker inhibitors of PfLDH (than gossypol) with IC50 values in the millimolar range (Ki’s 
not known).  The co-crystal structures revealed two binding modes for these compounds, one 
overlapping the pyruvate binding site and the other bridging the binding sites for the 
nicotinamide ring and pyruvate (Conners et al., 2005). PfLDH residues (Arg171, His195) that 
provide the major interactions with these inhibitors are identical in CpLDH.  The other 
interacting residue, Pro246, is replaced by an alanine in CpLDH but in this case the main 
chain oxygen atom is involved in the interaction. Since these compounds are much smaller 
than gossypol additional protein-ligand interactions involving the remainder of gossypol 
structure are not known.  However, these observations emphasize that in spite of the sequence 
similarity in the active site, subtle structural or conformational differences at or near the 
binding sites result in some degree of selectivity for a particular ligand.            
4.3. Comparison to Malate Dehydrogenase (MDH) 
LDH and MDH are homologous enzymes with a common protein fold and catalytic 
mechanism.  Recently, evolutionary relationships among various clades of LDH/MDHs have 
been analyzed and discussed in detail (Boucher et al., 2014.  In Apicomplexa, evolution of 
the ldh gene resulted from a small number of mutations of a duplicated ancestral mdh gene 
(Zhu & Keithly, 2002; Boucher et al., 2014).  In these organisms LDH evolved independently 
twice, resulting in two lineages in Plasmodium-related species and in Cryptosporidium.  In 
modern apicomplexan, LDH and MDH exhibit exquisite substrate specificity. The active site 
loop in these enzymes is highly significant not only in determining the rate of catalysis but 
also for substrate specificity (Bzik et al., 1993; Dunn et al., 1996; Waldman et al., 1988; 
Wilks et al., 1988).  In canonical LDHs residue 102 is glutamine, while the corresponding 
residue in all MDHs is arginine. A single mutation of this glutamine in canonical LDHs to 
arginine is sufficient to alter substrate specificity by three orders of magnitude (Wilks et al., 
1988).  Thus residue 102 is termed the ‘specificity residue.’  Notably, the corresponding 
residue in apicomplexan LDH is Lys, and in the crystal structures of these LDHs this residue 
remains excluded from the active site.  However, the most striking difference in the structures 
of these proteins is an insertion in the active site loop in LDH (Figure 7B).  This insertion 
results in an alteration of the ‘specificity residue’ to Trp107 in modern apicomplexan LDHs 
(Trp107 in TgLDH, 1PZF and Trp 94 in in PfLDH, 1T2D).   Mutation of this tryptophan 
residue to alanine in PfLDH results in a reduction of activity with pyruvate by five orders of 
magnitude (Boucher et al., 2014). 
The r.m.s.d. value for the superposition of CpLDH (NAD
+
/pyruvate complex) with 
CpMDH (PDBID: 2HJR) is 1.038 Å. The overall architecture of CpLDH is almost identical 
to that of CpMDH; the only significant difference occurs at the active site loop.  The CpLDH 
residues involved in substrate binding are conserved in CpMDH (Fig. 7A).  Boucher et al. 
(2014) suggested that Cryptosporidium LDHs are exceptional as they are clustered within the 
apicomplexan MDH clade separated from all other apicomplexan LDHs.  Thus, residue 102, 
which is lysine in all apicomplexan LDHs, is replaced by a glycine residue in CpLDH, and 
the five residue insertion seen in other apicomplexan LDHs is absent in CpLDH (Fig. 7B).   
4.4. APAD
+
 versus NAD
+
 binding 
Structural details of the cofactor binding sites in apicomplexan LDHs provide insights 
for understanding the basis of their preference for APAD
+
 over the natural substrate NAD
+
.  
In mammalian LDHs, NAD
+
 binding is favored by a hydrogen-bonding network formed by a 
serine residue (Ser161 in human), a highly conserved water molecule and the carboxyamide 
group (Fig. 8A).  When APAD
+
 is substituted for NAD
+
, there is a loss of these two hydrogen 
bonds, resulting in a lower affinity for APAD
+
.  However, in parasitic LDH structures only 
two hydrogen bonds are formed with NAD
+ 
(Fig. 8B), resulting in a lower affinity for this 
cofactor than the human enzyme . Furthermore, replacement of the conserved serine residue 
by Met163 in CpLDH (leucine in plasmodium or methionine in toxoplasma) allows a better 
packing environment for the acetyl group of APAD
+
. Finally, there is a small rotation of the 
pyridine ring around the glycosidic bond connecting N1 and C1, which moves the methyl 
group away from the carbonyl oxygen atoms of Ile138 and Met163 (Fig. 9).  For the 
LDH/APAD
+
/pyruvate structure this torsion angle is 132.2˚, while it ranges from 144.8˚ to 
146.0˚ for the three complexes that bind NAD+/NADH.  Although all of these changes are 
relatively small, together they are probably sufficient to explain the higher activity that 
PfLDH and CpLDH show with APAD
+
 compared to human LDH.  As in the case of 
plasmodium, the elevated activity of CpLDH with APAD
+
 may be useful as a diagnostic tool 
for detection of cryptosporidium. 
 
5. Conclusions 
Although the core of the CpLDH structure is similar to human LDH, it deviates in areas 
of functional significance.  The differences in enzymatic characteristics of CpLDH and 
human LDH isoforms are explained by the differences in the amino acid sequences and three-
dimensional structures of these proteins.  Many of the distinctive features of plasmodium and 
toxoplasma LDH are also conserved in the cryptosporidium enzyme.  This suggests that 
active site inhibitors developed against enzymes of one parasite may be useful for designing 
broad-spectrum anti-parasitic agents. 
Note 
 To preserve active-site nomenclature, LDHs are commonly numbered according to the 
initial assignment of residues from the X-ray structure of dogfish muscle LDH (Eventoff et 
al., 1977). Since the primary sequence was not available at that time, errors were made that 
consequently required the elimination of some numbers and the insertion of others. Insertions 
relative to this reference have a letter appended to the residue number (i.e., 73B). CpLDH 
consists of 321 residues that are numbered from the initiator methionine at residue 17 to the 
C-terminal residue Ala337. Insertions occur at six places in the sequence, where amino acid 
designations have a letter appended to the number. 
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Figure legends 1 
Figure 1. Sequence alignment 2 
Primary sequences of LDH from various organisms were aligned based on structural 3 
homology.  The labelling of secondary structural elements corresponds to the CpLDH 4 
structure.  The three black triangles indicate changes in the CpLDH sequence compared to 5 
the GenBank sequence. This figure was prepared using ESPript (Gouet et al., 1999). 6 
Figure 2. Enzymatic activity   7 
A. CpLDH activity for reduction of pyruvate was measured using buffer solutions at 8 
different pH.  Relative activity is plotted against pH values. 9 
B. CpLDH activity for oxidation of lactate was measured using buffer solutions at 10 
different pH.  Relative activity is plotted against pH values. 11 
C. Ki values for gossypol were determined for reduction of pyruvate with NADH at pH 12 
5.5.  Pyruvate concentration was 5 mM, and NADH concentrations were varied 13 
between 5-35 µM.  Gossypol concentrations were 0, 2.5, 7.5 and 10 µM.  14 
D. CpLDH activity was determined at saturating concentration of NADH (150 M) and 15 
varying concentrations of pyruvate by measuring the decrease in absorbance at 340 nm. 16 
Figure 3. Assembly of CpLDH and details of the cofactor binding pocket 17 
A. Cartoon drawing showing assembly of CpLDH in the asymmetric unit of the ternary 18 
complex with NAD
+
 and pyruvate.  The two monomers comprising the asymmetric unit 19 
are related by a noncrystallographic 2-fold axis that is approximately perpendicular to 20 
the page. Catalytic and NAD-binding domains of monomer A are depicted in magenta 21 
and light pink, respectively.  The helix connecting the two domains is shown in red and 22 
marine blue in the two subunits.  Catalytic and NAD-binding domains of the B subunit 23 
are colored cyan and light cyan, respectively, and the connecting helix is shown in 24 
slate.  NAD
+
 and pyruvate are shown as stick models.  25 
B. Close-up view of the NAD binding site in CpLDH, colored as in Figure 3(A).  NAD is 26 
shown as a stick model (carbon: white).  CpLDH residues in the NAD-binding site are 27 
also shown as stick models (carbon: rose or magenta). 28 
C. Surface drawing showing a close-up view of the adenine binding pocket in CpLDH.  1 
NAD is shown as a stick model (carbon: green).  CpLDH residues lining the pocket are 2 
shown as stick models (carbon: white) in the semi-transparent surface diagram.  3 
D. Stereoscopic view of the NAD-binding site in the CpLDH/NAD+/pyruvate complex.  4 
NAD (carbon: green), pyruvate (carbon: yellow) and the CpLDH residues (carbon: 5 
rose) forming hydrogen bonds to NAD and pyruvate are shown.  Arg171 and His195 6 
are also shown in stick model (carbon: magenta). Potential hydrogen bonds are 7 
illustrated in dotted lines.  Two water molecules near NAD are shown as red spheres. 8 
Figure 4. Changes in CpLDH structure upon substrate and cofactor binding  9 
A. Cartoon drawing showing superposition of the structures of apo CpLDH (magenta) and 10 
the ternary complex (cyan) with NAD
+
/pyruvate, highlighting the areas that show 11 
major changes. These areas are shown in blue on the complex structure, and the amino 12 
acid residues are labeled.   The active site loop observed in the complex (residues 99-13 
111, colored deep blue) is disordered in the apo-form.  NAD (carbon: green) and 14 
pyruvate (carbon: yellow) are shown as stick models. 15 
B. Close-up view of the region encompassing residues 138-145 of CpLDH in the apo and 16 
ternary complex structures.  Amino acid residues are shown as stick models: apo 17 
(carbon: rose) and complex (carbon: cyan). 18 
C.  Close-up view of the region encompassing residues 194-198 of CpLDH in the apo and 19 
ternary complex structures.  Amino acid residues are shown as stick models: apo 20 
(carbon: rose) and complex (carbon: cyan).  The His195 side chain is oriented towards 21 
the substrate in the complex. 22 
D.  Close-up view of the region encompassing residues 234-245 of CpLDH in the apo and 23 
ternary complex structures.  Amino acid residues are shown as stick models: apo 24 
(carbon: rose) and complex (carbon: cyan).  In the complex Trp236 moves closer to the 25 
substrate. 26 
Figure 5. Comparison of CpLDH with human LDH.  27 
A. Superposition of A monomers of the ternary complex CpLDH/NAD+/oxamate (cyan) 28 
and human LDH with NADH and oxamate (magenta) (1I0Z; Read et al., 2001).  NAD
+
 29 
in CpLDH is shown as a stick model (carbon: green), and oxamate is shown as a ball 30 
and stick model (carbon: yellow).  Three loop regions that show significant differences 1 
in conformation are labeled on the CpLDH cartoon.   2 
B. Detailed view of the loops covering the entrance to the active site. The labelled residues 3 
are from CpLDH. (2Fo-Fc electron density contoured at 1.2 for the residues in the two 4 
loops near the active site is displayed in supplementary figure).   5 
C. Detailed view of the antigenic loops in CpLDH (stick model) and human LDH (red).  6 
(2Fo-Fc electron density contoured at 1.2 for the loop residues in CpLDH is shown in 7 
supplementary figure).  8 
Figure 6. Comparison of CpLDH structure with PfLDH and TgLDH 9 
A. Cartoon diagram showing superposition of CpLDH structure (cyan) with PfLDH 10 
(yellow) and TgLDH (white) structures.  Structures of the CpLDH NAD+/pyruvate 11 
complex (4ND1), TgLDH/APAD/oxalate complex (1PZF) and PfLDH/NAD/oxalate 12 
complex (1T2D) were used for superposition.  NAD and pyruvate molecules in CpLDH 13 
are shown as stick models.   14 
B. A close up view showing the differences in the conformation near the active site of 15 
CpLDH.  Residues 101-102 that are different in CpLDH as compared to other 16 
apicomplexan LDHs are shown as stick models.  The conformation of the loop 17 
comprising residues 243-246 is also different in CpLDH. 18 
Figure 7.  Comparison of CpLDH, PfLDH and TgLDH with CpMDH 19 
A. Superposition of one monomer of CpLDH (4ND1, cyan) and CpMDH (2HJR, yellow) 20 
Only the active site region is shown because the differences are restricted to this area.  21 
Substrate binding residues of CpLDH and corresponding residues of CpMDH are 22 
shown as stick models (carbon atoms are colored same as the respective protein chain).  23 
CpLDH numbering is used for labeling except residue Arg94 of CpMDH, which is 24 
shown hydrogen bonded to citrate in the active site of CpMDH.  25 
B. Differences in the active site regions of CpLDH (blue), PfLDH (magenta) and TgLDH 26 
(grey) compared to CpMDH (yellow).  Glutamine 102 serves as the specificity residue 27 
for canonical LDHs. In all MDHs the corresponding residue is an arginine (Arg94 in 28 
CpMDH). In apicomplexan LDHs, residue 102 is lysine (Lys102 in TgLDH). In 29 
PfLDH and TgLDH there is a five residue insertion in the active site loop.  Due to the 30 
insertion, residue Trp107 becomes the specificity residue in PfLDH and CpLDH.  31 
However, LDHs of Cryptosporidium are exceptional among apicomplexan LDHs in 1 
that residue 102 in CpLDH is glycine. Residue 103 is an arginine in CpLDH, and it 2 
remains excluded from the active site. 3 
Figure 8. Hydrogen bonding interactions in the active site of LDH 4 
A. Human LDH NAD+/oxamate complex (1I0Z, Read et al., 2001) Stick diagram showing 5 
amino acid residues and water molecules forming hydrogen bonds with NAD and 6 
oxamate. 7 
B. CpLDH NAD+/oxamate complex (4ND1).  Amino acid residues involved in hydrogen 8 
bonding interactions with NAD and oxamate. 9 
Figure 9.  Comparison of NAD
+
 and APAD
+
 binding in CpLDH. The APAD
+
 carbon atoms 10 
are light green; the NAD+ carbons are light magenta. Important residues in the active site 11 
are included as stick models.   12 
 13 
 14 
 Table 1. Comparison of kinetic parameters for CpLDH, TgLDHs, PfLDH and human LDHs  
 CpLDH  PfLDH  Hs_M  Hs_H  TgLDH1  TgLDH2 
 Km Kcat Kcat/Km h  Km Kcat  Km Kcat  Km Kcat  Km Kcat  Km Kcat 
Pyruvte 197.3±0.1 124.0±5.6 0.63±0.04 0.69±0.00  30 27  170 18  55 13  120 35  800 4.6 
Lactat* 1.8±0.2 2.7±0.3 0.002±0.141 N.D.  12.0 17  11.0 4.9  13.0 3  8.0 1.6  54.0 5.8 
NADH 16.9±0.0 125.2±3.9 7.41±0.03 1.23±0.03  7 27  5 18  8 13  4.2 37  1.9 4.3 
APAH 16.6±0.0 231.7±7.2 13.96±0.03 1.08±0.06                
NAD
+
 30.3±0.0 3.3±0.1 0.11±0.03 1.04±0.07  86 17  93 4.9  37 3  348 1.3  640 0.45 
APAD
+
 8.5±0.1 14.9±0.8 1.75±0.05 0.69±0.08  123 51  56 0.24  37 0.17  50 34  78 13 
Units: Km in M, except for lactate* (mM); Kcat in min
-1
 ×10
-3
; Kcat/Km in M
-1
 min
-1
 ×10
-3
.  
Km: Concentration of substrate at which the catalytic rate is half-maximal; Kcat: number of substrate molecules processed per molecule 
of enzyme per unit of time. Kcat/Km: specifity constant; h :Hill coefficient (cooperativity); N.D.: not determined. 
Data for TgLDH taken from Dano et al., 2001; for PfLDH and human LDHs (Hs_H and Hs_M) are taken from Gomez et al., 1997. 
Hs_H and Hs_M refer to the H and M isoforms. 
Table 1
  
 
Table 2. Data-collection statistics  
 
 
†
Values in parentheses refer to the outermost resolution shell. 
 Apoenzyme NAD
+
 , pyruvate NADH, lactate NAD
+
, oxamate APAD
+
, pyruvate 
PDB ID 4ND5 4ND4 4ND3 4ND1 4ND2 
Crystal data 
Space group P3212  P3221 P3221 P3221 P3221 
Unit cell parameters (Å) a =b= 136.5 
c= 170.2 
a =b= 95.9 
c = 185.7 
a =b= 95.5 
 c = 186.0 
a =b= 94.816 
 c - 185.072 
a =b= 95.8 
 c = 185.6 
Vm (Å
3
 Da
-1
)   3.38 3.43 3.61 3.56 3.66 
Solvent content (%) 63.6 64.1 65.9 65.5 66.4 
 
Resolution range (Å) 20.0-2.10  
(2.17-2.10)
†
 
50.0-2.20  
(2.24-2.20) 
50.0-2.30 
(2.34-2.30) 
50.0-2.15  
(2.23-2.15) 
50.0-2.00  
(2.07-2.00) 
Overall I/ 9.2 7.7 9.0 6.7 9.5 
No. of unique reflections 100,051 51,036 44194 53149 67,287 
Multiplicity 3.8 (3.1) 7.3 (7.0) 8.7 (8.8) 6.7 (4.3) 10.7 (8.7) 
Completeness (%) 94.9 (64.6) 99.8 (100.0) 100.0 (99.5) 95.1 (65.7) 99.8 (97.7) 
Rmerge 0.062 (0.290) 0.081 (0.316) 0.064 (0.278) 0.074 (0.041) 0.054 (0.186) 
Table 2
Table 3. Refinement statistics  
 Apoenzyme NAD
+
 , pyruvate NADH, lactate NAD
+
, oxamate APAD
+
, pyruvate 
PDB ID 4ND5 4ND4 4ND3 4ND1 4ND2 
 
Resolution range (Å) 19.88-2.10  
(2.154-2.10)† 
49.64-2.20 
 (2.257-2.20) 
40.35-2.05 
 (2.102-2.049) 
47.41-2.15  
(2.21-2.15) 
49.61-2.00  
(2.052-2.00) 
Reflections (working set) 91,538 (3950) 45,828 (3316) 55,896 (4102) 45,370 (2221) 60,473 (4312) 
Reflections (test set) 4880 (191) 5134 (378) 6253 (441) 5088 (233) 6816 (476) 
R value 0.232 (0.292) 0.203 (0.245) 0.220  (0.315) 0.208 (0.291) 0.193 (0.218) 
Free R value 0.255 (0.326) 0.223 (0.283) 0.241 (0.309) 0.236 (0.319) 0.208 (0.248) 
No. of protein atoms 8909 4710 4710 4710 4710 
No. of hetero atoms 0 130 112 124 118 
No. of water molecules 194 260 206 150 416 
Total  no. of glycerol 0 5 [3+2]* 3 [2+1] 4 [3+1] 3 [2+1] 
Estimated coordinate error        
based on R value (Å) 
 
0.206 
 
0.205 
 
0.174 
 
0.209 
 
0.145 
based on free R value  (Å)  0.177 0.169 0.153 0.177 0.127 
R.m.s. deviations from ideal values  
Bond lengths (Å) 0.004 0.004 0.005 0.004 0.005 
Bond angles () 0.844 0.960 0.952 0.954 0.895 
Average B value§      
All atoms (Å
2
) 52.5 36.3 43.3 48.5 27.3 
Protein  50.4, 44.0, 53.6, 
67.6 
33.0, 40.3 39.1, 48.5 45.9, 52.1 25.1, 29.2 
Cofactor - 26.7, 35.3 31.8, 40.9 38.6, 47.7 19.4, 25.2 
Substrate/analog  30.6, 37.1 36.3- 39.4, 44.2 20.4, 24.6 
Glycerol  55.6, 53.4 55.7, 63.9 62.1, 59.4 37.6, 36.5 
Water 44.1 38.7 43.2 46.5 36.1 
      
Structure quality 
Clashscore (percentile) 3.06 (99) 1.24 (100) 1.34 (100) 1.34 (100) 1.55 (100) 
MolProbity score (percentile) 1.36 (99) 1.04 (100) 0.99 (100) 1.06 (100) 0.95 (100) 
Ramachandran favored (%) 96.12 96.83 97.30 96.83 97.78 
Ramachandran allowed (%) 3.63 2.54 2.22 2.69 2.06 
Ramachandran outliers (%) 0.25 0.63 0.48 0.48 0.16 
 
Table 3
 2 
Rotamer outliers (%) 0.31                        0.19                        0.39                        0.00                        0.19 
  
† numbers in parenthesis are for highest resolution shell 
*number of glycerol molecule associated with each monomer in the asymmetric unit. 
§values for different subunits in asymmetric unit are separated by comma 
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Enzymatic characterization and crystallographic analysis Cryptosporidium parvum Lactate 
dehydrogenase reveal distinctive features of the parasitic enzyme and suggest that it is an 
exceptional member in the apicomplexan lactate dehydrogenase family. 
Highlights (for review)
Supplementary Figure S2 
Electron density for substrate and cofactor in the four ternary complexes. For A-D, Fo-Fc 
electron density maps were generated after removal of ligands.  Electron density contoured at 3 
is displayed around each ligand. 
(A) CpLDH/NAD
+
/pyruvate (4ND4). 
(B) CpLDH/NADH/lactate (4ND3). 
(C) CpLDH/NAD
+
/oxamate (4ND1). 
(D) CpLDH/APAD
+
/pyruvate (4ND2). 
For E and F, stereo diagrams showing 2Fo-Fc electron density map are contoured at 1.2 around 
ligands, amino acid residues and selected water molecules. (E) CpLDH/NADH/lactate (4ND3). 
(F) CpLDH/NAD/oxamate (4ND1).  
Supplementary Figure S1
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